[go: up one dir, main page]

WO2018047013A8 - Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same - Google Patents

Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same Download PDF

Info

Publication number
WO2018047013A8
WO2018047013A8 PCT/IB2017/001312 IB2017001312W WO2018047013A8 WO 2018047013 A8 WO2018047013 A8 WO 2018047013A8 IB 2017001312 W IB2017001312 W IB 2017001312W WO 2018047013 A8 WO2018047013 A8 WO 2018047013A8
Authority
WO
WIPO (PCT)
Prior art keywords
making
dithiole
thione
pyrazin
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2017/001312
Other languages
French (fr)
Other versions
WO2018047013A1 (en
Inventor
Anthony Chris GARLAND
Barbara-jean Anne BORMANN-KENNEDY
Bomi FRAMROZE
Bret Berner
Michael Edward GRASS
Casey Keith JAGER
Corey Jay Bloom
Mark Joseph KASTANTIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ST IP Holding AG
Original Assignee
ST IP Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ST IP Holding AG filed Critical ST IP Holding AG
Priority to KR1020197010583A priority Critical patent/KR102658015B1/en
Priority to EP17808567.6A priority patent/EP3509642A1/en
Priority to JP2019535993A priority patent/JP2019531344A/en
Priority to AU2017323504A priority patent/AU2017323504A1/en
Priority to CN201780069787.9A priority patent/CN109996562A/en
Publication of WO2018047013A1 publication Critical patent/WO2018047013A1/en
Publication of WO2018047013A8 publication Critical patent/WO2018047013A8/en
Priority to US16/351,058 priority patent/US11426403B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This disclosure provides, among other things, compositions comprising quantities of oltipraz crystals, as well as method of making such compositions, and method of treating patients using such compositions.
PCT/IB2017/001312 2016-09-12 2017-09-12 Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same Ceased WO2018047013A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1020197010583A KR102658015B1 (en) 2016-09-12 2017-09-12 Preparations of 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiol-3-thione, and methods of making and using the same
EP17808567.6A EP3509642A1 (en) 2016-09-12 2017-09-12 Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
JP2019535993A JP2019531344A (en) 2016-09-12 2017-09-12 Formulas of 4-methyl-5- (pyrazin-2-yl) -3H-1,2-dithiol-3-thione and methods for their production and use
AU2017323504A AU2017323504A1 (en) 2016-09-12 2017-09-12 Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
CN201780069787.9A CN109996562A (en) 2016-09-12 2017-09-12 The preparation and its preparation and application of 4- methyl -5- (pyrazine -2- base) -3H-1,2- dithiole -3- thioketones
US16/351,058 US11426403B2 (en) 2016-09-12 2019-03-12 Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, and methods of making and using same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201611031045 2016-09-12
IN201611031045 2016-09-12
US201662412681P 2016-10-25 2016-10-25
US62/412,681 2016-10-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/351,058 Continuation US11426403B2 (en) 2016-09-12 2019-03-12 Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, and methods of making and using same

Publications (2)

Publication Number Publication Date
WO2018047013A1 WO2018047013A1 (en) 2018-03-15
WO2018047013A8 true WO2018047013A8 (en) 2018-05-24

Family

ID=61562532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/001312 Ceased WO2018047013A1 (en) 2016-09-12 2017-09-12 Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same

Country Status (1)

Country Link
WO (1) WO2018047013A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3762104A2 (en) * 2018-03-07 2021-01-13 ST IP Holding AG Combination compositions and therapies comprising 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, and methods of making and using same
SG11202102653WA (en) * 2018-09-18 2021-04-29 St Ip Holding Ag Rotomeric isomers of 4-alkyl-5-heteroaryl-3h-1,2- dithiole-3-thiones
CN111068058A (en) * 2020-01-15 2020-04-28 云南中医药大学 Application of PGC-1α activator in the preparation of drugs for the treatment of sepsis
TW202200144A (en) 2020-03-16 2022-01-01 瑞士商Ｓｔ知識產權控股公司 Rotomeric isomers of 4-alkyl-5-heteroaryl-3h-1,2-dithiole-3-thiones
US11135220B1 (en) * 2020-04-08 2021-10-05 St Ip Holding Ag Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3156369A (en) 1962-09-19 1964-11-10 Ethicon Inc Bicameral container
NL171985C (en) 1976-02-10 1983-06-16 Rhone Poulenc Ind METHOD FOR PREPARING PREPARATIONS WITH ACTION AGAINST SCHISTOSOMIASIS, THE PREPARED PREPARATIONS SO GIVEN AND METHOD FOR PREPARING 1,2-DITHIOOL COMPOUNDS.
IT1292677B1 (en) 1997-02-28 1999-02-11 Bormioli Metalplast Spa PACKAGING TO KEEP THE PRODUCTS SEPARATE BEFORE USE.
CA2408152A1 (en) 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
KR100491318B1 (en) * 2002-11-26 2005-05-24 씨제이 주식회사 Method for preparing oltipraz
KR100629771B1 (en) * 2004-01-27 2006-09-28 씨제이 주식회사 Method for preparing oltipraz with reduced or amorphous crystallinity
ATE420037T1 (en) 2005-07-15 2009-01-15 Bormioli Rocco & Figlio Spa CONTAINER WITH A CUTTING DEVICE FOR SUBSTANCES TO BE MIXED WITH LIQUIDS AT THE MOMENT OF USE, IN PARTICULAR FOR SINGLE DOSE CONTAINERS
GB0704718D0 (en) 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
WO2011101114A2 (en) 2010-02-16 2011-08-25 Teva Branded Pharmaceutical Products R&D, Inc. An inhalable pharmaceutical composition
EP2717860A4 (en) * 2011-06-08 2014-11-05 Sti Pharma Llc WATER-SOLUBLE PHARMACEUTICAL ORGANIC PREPARATION WITH CONTROLLED ABSORPTION ADMINISTERED ONCE DAILY
WO2013043553A1 (en) * 2011-09-22 2013-03-28 Glaxosmithkline Llc Pyrrolopyridinone compounds and methods for treating hiv
CN104703584B (en) 2012-02-28 2019-05-31 艾塞尤提卡控股公司 Inhalable pharmaceutical composition
MX2015015132A (en) 2013-04-29 2016-02-18 Sanofi Sa Inhalable pharmaceutical compositions and the inhaler devices containing them.
WO2016207914A2 (en) 2015-06-25 2016-12-29 St Ip Holding Ag Methods for preparing oltipraz

Also Published As

Publication number Publication date
WO2018047013A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
EP3898797A4 (en) Foaming agent compositions containing 1,2,2-trifluoro-1-trifluoromethylcyclobutane, and methods of foaming
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
WO2018047013A8 (en) Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
PH12018502268A1 (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
MX2020010369A (en) Implantable particles and related methods.
EP3672973A4 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
EP3976595A4 (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
EP4385521A3 (en) Storage stable compositions and methods for the treatment of refractive errors of the eye
PH12015502792A1 (en) Crystalline bromodomain inhibitors
EP4427808A3 (en) Compositions and methods for reducing ocular neovascularization
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
WO2017083431A3 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
HK1254608A1 (en) Improved formulations of deferasirox and methods of making the same
EP3279207A4 (en) Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof
EP3697791A4 (en) Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof
ZA201807446B (en) Improved drug formulations
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
IL272767A (en) Composition comprising wharton's jelly, method for preparing same and uses thereof
MX2024010625A (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof.
WO2019171174A3 (en) Combination compositions and therapies comprising 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, and methods of making and using same
PH12019500530A1 (en) Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
AU2017323504A8 (en) Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1, 2-dithiole-3-thione, and methods of making and using same
CA3003108A1 (en) Storage stable composition comprising rifaximin alpha

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17808567

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase in:

Ref document number: 2019535993

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase in:

Ref country code: DE

ENP Entry into the national phase in:

Ref document number: 20197010583

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase in:

Ref document number: 2017323504

Country of ref document: AU

Date of ref document: 20170912

Kind code of ref document: A

ENP Entry into the national phase in:

Ref document number: 2017808567

Country of ref document: EP

Effective date: 20190412